NVS evidently passed on GNLB’s NS5A program: see the bold-faced section of this PR about ¾ of the way down: #msg-11431616.
GNLB is still nominally partnered with NVS on a non-nuke HCV polymerase inhibitor (#msg-30203067), but this program is in the ultra-slow lane and it’s doubtful that it was the impetus for the GSK buyout.
I think GSK is almost certainly buying GNLB for the NS5A program. The HEV vaccine is perhaps a modest kicker.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.